Gapping up
In reaction to earnings/guidance:
- FIGS +2% (FY21 guidance)
Other news:
- ARNA +92.5% (to be acquired by Pfizer (PFE) for $100/share)
- FHTX +38.3% (Foghorn Therapeutics and Lilly (LLY) form strategic collaboration for novel oncology targets; Foghorn to receive $300 mln upfront and an equity investment by Lilly of $80 mln at $20 per share)
- BLU +27.9% (topline results from its Phase 2b SOOTHE trial of BLU-5937 for the treatment of refractory chronic cough)
- BLUE +11.3% (New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21 and Published in NEJM)
- HOG +10.4% (Harley-Davidson's LiveWire to merge with AEA-Bridges Impact Corp (IMPX) in SPAC deal)
- MREO +8.7% (presentation of data from the initial seven patients in an investigator-sponsored study of alvelestat in patients with BOS following hematopoietic stem cell transplantation)
- EDIT +8.6% (Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting)
- SANA +7.6% (Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs)
- TGTX +6.2% (Announces Data Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting)
- MNOV +5.9% (received a Notice of Allowance from the US Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis)
- BKEP +4.9% (to acquire an asphalt terminal and 200-acre industrial park in Colorado)
- RAM +3.9% (InfiniteWorld plans to become a publicly traded company via a merger with Aries I Acquisition Corporation)
- SGMO +3.5% (Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy)
- RYAN +3.4% (signed a definitive agreement to acquire certain assets of Keystone Risk Partners)
- SRAD +3.1% (positive Barrons article)
- NVAX +3.1% (files for EUA of COVID-19 Vaccine in the United Arab Emirates)
- EPZM +2.9% (Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting)
- IMGN +2.7% (Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza and Venclexta in Relapsed/Refractory Acute Myeloid Leukemia at ASH)
- OBSV +2.3% (names Will Brown as CFO)
- CSIQ +2% (Canadian Solar's CSI Solar subsidiary receives approval for its proposed listing by the Shanghai Stock Exchange)
- BMY +1.9% (announces 10.2% dividend increase and additional $15 billion share repurchase authorization)
- NUVB +1.9% (FDA clears IND application for NUV-422 as treatment for prostate cancer_)
- SVFC +1.8% (Symbotic to become a public company in partnership with SoftBank)
- AAPL +1.3% (positive Barrons article)
Analyst comments:
- GPRO +3% (upgraded to Outperform from Neutral at Wedbush)
- GMED +2.6% (upgraded to Buy from Underperform at BofA Securities)
- KO +1.1% (upgraded to Overweight from Neutral at JP Morgan)
- NATI +1.1% (upgraded to Neutral from Underweight at JP Morgan)